GLP-1 gastroparesis symptoms and the gaps

Gastroparesis, meaning a stomach that empties far too slowly, is one of the side effects that worries people starting semaglutide or tirzepatide the most. A systematic review published in PLoS One on 13 August 2026 gathered every published case attributed to a GLP-1 receptor agonist. It found 12 case reports covering 13 patients^[1]. That count matters as much as the findings do. The published record here is small, and it is built from individual stories rather than from counted rates.

What gastroparesis actually is

Gastric emptying is the rate at which food leaves the stomach and passes into the small intestine. GLP-1 drugs slow it down on purpose. That slowing is part of how they blunt blood-sugar spikes after meals and make people feel full sooner. Gastroparesis is the point where the slowing stops being useful and becomes an illness: vomiting that will not settle, an inability to keep food or fluid down, and a stomach still holding its contents hours after a meal.

Who the 13 patients were

The reviewers searched PubMed, Embase, Scopus and Web of Science from inception to 14 October 2025, following the PRISMA 2020 reporting standard^[1]. The patients they found ranged from 18 to 74 years old and were mostly female. Semaglutide was the drug involved in 7 of the 13 cases. Liraglutide, dulaglutide and exenatide accounted for the rest, including one case that followed an overdose.

Timing varied a lot. Symptoms started anywhere from within 24 hours of a dose to roughly three months after treatment began. Five patients became symptomatic inside the first week. Four fell in the one to three month window. Dose escalation was a common trigger, which fits the way tirzepatide and the other incretin drugs are titrated upward in steps.

The complaints were the familiar gut side effects turned up loud: nausea, vomiting, abdominal pain, bloating, early satiety and an inability to tolerate food by mouth.

How doctors confirmed it

Six of the patients had gastric emptying scintigraphy, a scan that tracks a radiolabelled meal as it leaves the stomach. All six showed delayed emptying, with between 24% and 88% of the meal still sitting in the stomach at the four-hour mark^[1]. Others were worked up with upper endoscopy or abdominal CT, which showed a distended stomach or retained food. No single test defined the diagnosis across the series. That inconsistency is part of why these cases are hard to pool.

What happened to the patients

Stopping the drug sat at the centre of management in every reported case. Alongside that, care in the reviewed cases included antiemetics, prokinetic drugs such as metoclopramide and intravenous fluids. A minority needed a nasogastric tube to decompress the stomach. Hospital stays ran three to ten days, with patients kept off food for a period and then moved back to liquids and small meals.

Outcomes were good in nearly all of the cases. Symptoms resolved once the GLP-1 drug was withdrawn, and where scintigraphy was repeated it showed gastric emptying back to normal. The review reports no deaths and no lasting complications. One patient had a drawn-out course with symptoms persisting through the hospital stay, and one developed euglycaemic diabetic ketoacidosis. Nobody in the series was restarted on the drug afterwards, so the review says nothing about whether the problem returns on rechallenge^[1].

The drug labels already say this

None of this is news to regulators. The US label for Ozempic states plainly that the drug "is not recommended in patients with severe gastroparesis"^[2]. The Mounjaro label carries the same wording for tirzepatide and adds that the drug "delays gastric emptying," with a delay that "is largest after the first dose and this effect diminishes over time"^[3]. Milder gut effects are very common by comparison. In trials, 73% of adults on Wegovy reported a gastrointestinal adverse reaction, against 47% on placebo^[4].

What this evidence cannot tell you

A systematic review of case reports has no denominator. It can describe what published gastroparesis cases looked like. It cannot tell you how many people taking semaglutide go on to develop it, because nobody counted the people who did not. The authors say as much: the true incidence and risk magnitude cannot be determined from this material^[1]. Case reports also reach print because they are unusual, which tilts the picture toward the dramatic end.

For a rate, you need a different study design. A 2026 cohort study of 313,342 matched pairs of US adults with type-2 diabetes found severe motility events (a composite of severe constipation, gastroparesis and obstruction) at 1.02 per 100 person-years on GLP-1 based therapy, against 0.75 on an SGLT-2 inhibitor. That is a hazard ratio of 1.37, and the absolute risk stayed at 1% or below^[5]. A 2024 review in the Journal of Clinical Endocrinology and Metabolism adds two useful qualifiers: the gastric-emptying effect fades with continued treatment, and it is smallest in people whose stomachs were already slow before they started^[6].

If you are taking one of these drugs

Read the case series as a description of a rare failure mode, not as a probability that applies to you. The ordinary experience on semaglutide, tirzepatide or retatrutide is nausea that eases as the body adjusts. Persistent vomiting is a different matter. Vomiting you cannot stop, or being unable to keep fluids down for more than a day, is a reason to contact a clinician rather than wait it out or manage it at home. Dehydration from vomiting is the documented route to acute kidney injury named in the Ozempic label^[2].

Decisions about pausing or changing a dose belong with your prescriber, not with a search result. Supply and prescribing rules also differ by country, and our United States regulation page and United Kingdom regulation page cover where each drug stands. This article is educational and is not medical advice.